Free Trial

Fortress Biotech Q4 2022 Earnings Report

Fortress Biotech logo
$1.74 +0.02 (+1.16%)
(As of 05:45 PM ET)

Fortress Biotech EPS Results

Actual EPS
-$4.50
Consensus EPS
-$3.30
Beat/Miss
Missed by -$1.20
One Year Ago EPS
N/A

Fortress Biotech Revenue Results

Actual Revenue
$16.40 million
Expected Revenue
$25.20 million
Beat/Miss
Missed by -$8.80 million
YoY Revenue Growth
N/A

Fortress Biotech Announcement Details

Quarter
Q4 2022
Time
N/A
Did You See Trump’s Bombshell Exec. Order 001? (Ad)

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry. 

Fortress Biotech Earnings Headlines

Missed Nvidia? Buy Elon Musk’s “Silent Partner”
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
Fortress Biotech price target raised to $15 from $13 at Roth MKM
Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright
See More Fortress Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fortress Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fortress Biotech and other key companies, straight to your email.

About Fortress Biotech

Fortress Biotech (NASDAQ:FBIO), a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

View Fortress Biotech Profile

More Earnings Resources from MarketBeat

Upcoming Earnings